Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes (R01 Clinical trial Required)
Funding Opportunity RFA-DK-23-011 from the NIH Guide for Grants and Contracts. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) that were developed for the treatment of type 2 diabetes (T2D) have significant protective effects for cardiac and renal diseases for people with and without diabetes. However, SGLT2i are not currently approved for individuals with type 1 diabetes (T1D) and there is an increased risk of diabetic ketoacidosis (DKA) for this population. Despite this concern, these drugs are increasingly being prescribed off-label for people with T1D. Continuous ketone monitoring (CKM) is a rapidly evolving tec...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 30, 2024 Category: Research Source Type: funding
Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes (T1D) Research (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-21-031 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development and/or validation of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community [e.g. glucagon and other pro-glucagon derived peptides, C-peptide, insulin, pro-insulin, Glycated CD59, Islet Amyloid Polypeptide (IAPP), Chromogranin A (CgA), and chromogranin B (CgB)]. The proposed assays should be highly reproducible, easi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 14, 2022 Category: Research Source Type: funding
Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional)
Funding Opportunity RFA-CA-21-021 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) invites research grant proposals for transdisciplinary studies that will enhance our knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation and increased cancer risk. Through this Funding Opportunity Announcement (FOA), the Metabolic Dysregulation and Cancer Risk Program will focus on metabolic dysregulation as the key process linking obesity with cancer risk. For the purpose of this FOA, metabolic dysregulation is defined as alterations in glucose utilization and st...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 6, 2021 Category: Research Source Type: funding
The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional)
Funding Opportunity RFA-DK-21-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions and organizations proposing original research aimed at the characterization of the function of neoepitopes and neoantigens in type 1 diabetes. This includes the function that post-translational modifications might have in the humoral and cell mediated autoimmune responses and overall in the etiology and pathophysiology of type 1 diabetes. Proposals that include the discovery of neoantigens or neoepitopes are within the scope of this solicitation, but should ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 17, 2021 Category: Research Source Type: funding
Limited Competition for the Continuation of the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
Funding Opportunity RFA-DK-18-509 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator of the Coordinating Center (TNCC) that is currently supporting the research being performed by the Type 1 Diabetes TrialNet network. This FOA will support the TNCC in its oversight of the screening of relatives of individuals with type 1 diabetes (T1D) for monitoring and possible inclusion in intervention studies aimed at preservation of insulin-producing cells. The FOA will also support the TNCC in its design, conduct and conti...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 10, 2019 Category: Research Source Type: funding
Limited Competition for the Continuation of the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator of the Coordinating Center (TNCC) that is currently supporting the research being performed by the Type 1 Diabetes TrialNet network. This FOA will support the TNCC in its oversight of the screening of relatives of individuals with type 1 diabetes (T1D) for monitoring and possible inclusion in intervention studies aimed at preservation of insulin-producing cells. The FOA will also support the TNCC in its design, conduct and continuation of intervention studies in individuals at early pre-clinical stages of T1D...
Source: NIDDK Funding Opportunities - January 10, 2019 Category: Endocrinology Source Type: funding
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)
Funding Opportunity PAR-18-892 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by prev...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 7, 2018 Category: Research Source Type: funding
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)
Funding Opportunity PAR-18-893 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by prev...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 7, 2018 Category: Research Source Type: funding
Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (R01 Clinical Trial Required)
Funding Opportunity RFA-DK-17-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing clinical studies of the use of current and emerging technologies for monitoring of blood glucose and insulin administration in older adults. (aged 65 years or older) Older adults may have increased vulnerability to hypoglycemia, cognitive impairment and/or multiple co-morbidities which may affect the risks and benefits of these technologies in this population. This research is intended to improve health, glucose control and quality of...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 15, 2018 Category: Research Source Type: funding
The Characterization and Discovery of Novel Autoantigens and Epitopes in Type 1 Diabetes (R01 Clinical Trial Optional)
Funding Opportunity RFA-DK-17-031 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research aimed at the characterization and discovery of neoantigens and neoepitopes in type 1 diabetes. These include the characterization of the humoral and cell mediated autoimmune responses elicited by these neoepitopes and neoantigens and their role in the etiology and pathophysiology of type 1 diabetes. These studies should be integrated with the present knowledge of established epitopes and antigens (e.g. autoantibodies...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 15, 2018 Category: Research Source Type: funding
The Characterization and Discovery of Novel Autoantigens and Epitopes in Type 1 Diabetes (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research aimed at the characterization and discovery of neoantigens and neoepitopes in type 1 diabetes. These include the characterization of the humoral and cell mediated autoimmune responses elicited by these neoepitopes and neoantigens and their role in the etiology and pathophysiology of type 1 diabetes. These studies should be integrated with the present knowledge of established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8T).Salvatore Sechi, Ph.D. | RFA-DK-17-031 (Sour...
Source: NIDDK Funding Opportunities - February 15, 2018 Category: Endocrinology Source Type: funding
Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (R01 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing clinical studies of the use of current and emerging technologies for monitoring of blood glucose and insulin administration in older adults. (aged 65 years or older) Older adults may have increased vulnerability to hypoglycemia, cognitive impairment and/or multiple co-morbidities which may affect the risks and benefits of these technologies in this population. This research is intended to improve health, glucose control and quality of life of older patients with type 1 diabetes Only human studies will be considered...
Source: NIDDK Funding Opportunities - February 15, 2018 Category: Endocrinology Source Type: funding
The Characterization and Discovery of Novel Autoantigens and Epitopes in Type 1 Diabetes (R01 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research aimed at the characterization and discovery of neoantigens and neoepitopes in type 1 diabetes. These include the characterization of the humoral and cell mediated autoimmune responses elicited by these neoepitopes and neoantigens and their role in the etiology and pathophysiology of type 1 diabetes. These studies should be integrated with the present knowledge of established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8T).Salvatore Sechi, Ph.D. | RFA-DK-17-031 (Sour...
Source: NIDDK Funding Opportunities - February 15, 2018 Category: Endocrinology Source Type: funding
Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (R01 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing clinical studies of the use of current and emerging technologies for monitoring of blood glucose and insulin administration in older adults. (aged 65 years or older) Older adults may have increased vulnerability to hypoglycemia, cognitive impairment and/or multiple co-morbidities which may affect the risks and benefits of these technologies in this population. This research is intended to improve health, glucose control and quality of life of older patients with type 1 diabetes Only human studies will be considered...
Source: NIDDK Funding Opportunities - February 15, 2018 Category: Endocrinology Source Type: funding
Immune System Engineering For Targeted Tolerance in Type 1 Diabetes (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-17-020 from the NIH Guide for Grants and Contracts. Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments. Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomater...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 14, 2018 Category: Research Source Type: funding
